Oncology Sponsored Collaboration & personalisation in rare disease R&D, with AO... For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.
R&D On JPM2026 and healthcare investment today, with Jonah Comst... Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
Patients On addressing drug waste and ensuring access, with Jeff Harp... The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.
Digital JPM2026: Broadening AI drug discovery to include the lab, wi... Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.
Oncology On AI and equity in the cancer setting, with Mohit Manrao Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.
Digital JPM2026: AI diagnostics and translational research, with And... On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.